Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.
Anoro Ellipta should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD, or as rescue therapy for the treatment of acute episodes of ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ Ellipta ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
Avoid co-administration of Anoro with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects such as cardiovascular effects, worsening of ...
Umeclidinium 62.5mcg, vilanterol 25mcg; per inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...
Anoro Ellipta side effects Anoro Ellipta can cause mild or serious side effects. The following lists contain some of the key side effects that may occur while taking Anoro Ellipta. These lists do not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results